Informations générales (source: ClinicalTrials.gov)
A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced Solid Tumors
Interventional
Phase 1
Janssen Research & Development, LLC (Voir sur ClinicalTrials)
octobre 2025
août 2028
07 juin 2026
The purpose of this study is to determine safe and effective dose (recommended phase 2
doses [RP2Ds]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how
safe JNJ-89862175 is at the RP2Ds in Part 2 (dose expansion) in participants with
advanced stage solid tumors.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Anas GAZZAH | 29/06/2026 12:15:06 | Contacter | ||
Critères
Tous
- Participants must have histologically or cytologically confirmed, metastatic or
unresectable solid tumor of lung adenocarcinoma, renal cell carcinoma (RCC): clear
cell or papillary carcinoma, endometrioid ovarian cancer and endometrioid uterine
carcinoma
- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1 at
screening
- Participants on study drug and for 4 months after the last dose of study drug must
not breastfeed or be pregnant, not donate gametes (that is, eggs or sperms) or
freeze for future use for the purposes of assisted reproduction and wear an external
condom
Exclusion Criteria:
- Active central nervous system (CNS) involvement unless clinically stable
- History of clinically significant cardiovascular disease within 6 months prior to
signing informed consent
- History of solid organ or hematologic stem cell transplantation
- Known allergies, hypersensitivity, or intolerance to excipients of JNJ-89862175
- Has prior or concurrent second malignancy (other than the disease under study) in
which the natural history or treatment is likely to interfere with safety endpoints
or efficacy of the study drug